Arrayit Hires Docro to Smooth FDA Path for OvaDx Test

Arrayit is hoping to submit OvaDx, an array-based pre-symptomatic ovarian cancer test that includes 100 proteomic biomarkers, to the FDA later this year.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.